[EN] FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDAZINE FUSIONNÉS UTILISÉS COMME INHIBITEURS DE NLRP3
申请人:[en]TAKEDA PHARMACEUTICAL COMPANY LIMITED
公开号:WO2023194964A1
公开(公告)日:2023-10-12
Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein α, β, m, R5, R6, R7, R9, R10, R11, Ra, Rb, X1, X2, X3, X4and X8are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (I), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with NLRP3.